
Name
CMFPT
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for CMFPT
Name
Alternate Names
5-Fluorouracil
5-Fluracil
Adrucil
Efudex
Fluoroplex
Fluracil
Fluril
Oracil
Ro 2-9757
WR-69596
Abbreviations
5-FU
5FU
FU
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
019893
19893
Primary Site
Breast- adjuvant setting and advanced disease
colorectal- adjuvant setting and advanced disease
GI malignancies: anal, esophageal, gastric and pancreatic
Hepatoma
Ovarian cancer
Histology
None
Remarks
Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Coding
This drug should be coded
Name
Alternate Names
Alpha-Tamoxifen
Apo-Tamox
Dom-Tamoxifen
Gen-Tamoxifen
ICI-46474
Nolvadex
Nolvadex-D
Novo-Tamoxifen
PMS-Tamoxifen
Tamofen
Tamone
Tamoplex
Tamoxifen
Tamoxifen Citrate
Soltamox
Abbreviations
TAM
TMX
Category
Hormones and hormonal mechanisms
Subcategory
Nonsteroidal antiestrogen
NSC Number
180973
Primary Site
Breast
Histology
None
Remarks
A nonsteroidal antiestrogenic agent with combined partial-estrogen-agonist activity. FDA approved uses on breast cancer and risk reduction for women with high risk of developing breast cancer.
Literature shows that Tamoxifen is being prescribed for recurrent/relapsed ovarian cancer.
Literature shows that Tamoxifen is being prescribed for recurrent/relapsed ovarian cancer.
Coding
This drug should be coded
Name
Alternate Names
Amethopterin
Antifolan
CL-14377
Folex
Methotrexate Sodium
Mexate
Mexate AQ
Rheumatrex
WR-19039
Abbreviations
MTX
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
740
000740
Primary Site
Bladder cancer
Breast
Gestational trophoblastic cancer
lymphoma
Meningeal leukemia
Non-Hodgkin lymphoma
Osteogenic sarcoma
Histology
None
Remarks
FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.
Coding
This drug should be coded
Name
Alternate Names
Alti-Prednisone
Alto-Pred
Ancortone
Apo-Prednisone
Colisone
Cortan
Dacortin
Delta-Dome#
Deltasone
Deltra
Fernisone Buffered
Keysone
Liquid Pred
Meticorten
Novo-Prednisone
Orasone
Panasol
Paracort#
Prednicen M
SK-Prednisone
Sterapred DS
Ultracorten
Winpred
Abbreviations
PDN
PRD
PRED
Category
Hormones and hormonal mechanisms
Subcategory
Glucocorticoid
NSC Number
10023
010023
Primary Site
Histology
None
Remarks
Code Prednisone when it is part of a drug regimen.
Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.
Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.
Coding
Please see remarks for additional information
Name
Alternate Names
Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719
Abbreviations
CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
026271
26271
Primary Site
Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor
Histology
None
Remarks
An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent
Coding
This drug should be coded
